Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15797539,extraction recovery,"The extraction recovery of lauroyl-indapamide was ranged from 76.5 to 82.6%, and the calibration curve had a good linearity in the range of 0.048-200 microg/ml (r = 0.9976).",Determination of lauroyl-indapamide in rat whole blood by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15797539/),%,76.5 to 82.6,11806,DB00808,Indapamide
≥,27037980,recoveries,The recoveries from spiked control samples were ≥86.16% for all analytes and IS.,"Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037980/),%,86.16,32966,DB00808,Indapamide
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],23.179,39047,DB00808,Indapamide
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,0.729,39048,DB00808,Indapamide
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,1.429,39049,DB00808,Indapamide
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],26.998,39050,DB00808,Indapamide
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],27.117,39051,DB00808,Indapamide
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],1.834,39052,DB00808,Indapamide
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,8.792,39053,DB00808,Indapamide
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,40.699,39054,DB00808,Indapamide
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],54.828,39055,DB00808,Indapamide
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],77.113,39056,DB00808,Indapamide
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],18.994,39057,DB00808,Indapamide
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,3.417,39058,DB00808,Indapamide
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,16.626,39059,DB00808,Indapamide
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],385.829,39060,DB00808,Indapamide
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],410.728,39061,DB00808,Indapamide
,7957454,area under the curve,"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],281,46610,DB00808,Indapamide
,7957454,area under the curve,"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],2178,46611,DB00808,Indapamide
,7957454,area under the curve,"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],739,46612,DB00808,Indapamide
,7957454,area under the curve,"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],716,46613,DB00808,Indapamide
,7957454,area under the curve,"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],1597,46614,DB00808,Indapamide
,7957454,time 0 to infinity (AUC(0-infinity)),"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],281,46615,DB00808,Indapamide
,7957454,time 0 to infinity (AUC(0-infinity)),"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],2178,46616,DB00808,Indapamide
,7957454,time 0 to infinity (AUC(0-infinity)),"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],739,46617,DB00808,Indapamide
,7957454,time 0 to infinity (AUC(0-infinity)),"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],716,46618,DB00808,Indapamide
,7957454,time 0 to infinity (AUC(0-infinity)),"For the area under the curve, calculated from time 0 to infinity (AUC(0-infinity)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml.",Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957454/),[h·ng] / [ml],1597,46619,DB00808,Indapamide
,20712133,total run time,The total run time of the LC-MS/MS method was 3.5 min per sample as opposed to 11 min for the other method.,Comparison of liquid chromatography-ultraviolet and chromatography-tandem mass spectrometry for the determination of indapamide in human whole blood and their applications in bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20712133/),[min] / [sample],3.5,62268,DB00808,Indapamide
,20712133,total run time,The total run time of the LC-MS/MS method was 3.5 min per sample as opposed to 11 min for the other method.,Comparison of liquid chromatography-ultraviolet and chromatography-tandem mass spectrometry for the determination of indapamide in human whole blood and their applications in bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20712133/),min,11,62269,DB00808,Indapamide
,3311532,bioavailability,The bioavailability is about 15% and it has a half-life of 2 to 3 hours.,Clinical pharmacokinetics of some newer diuretics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,15,68489,DB00808,Indapamide
,3311532,half-life,The bioavailability is about 15% and it has a half-life of 2 to 3 hours.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,2 to 3,68490,DB00808,Indapamide
,3311532,Renal,"Renal and non-renal clearance are 1.32 and 5.4 L/h, respectively.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],1.32,68491,DB00808,Indapamide
,3311532,non-renal clearance,"Renal and non-renal clearance are 1.32 and 5.4 L/h, respectively.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],5.4,68492,DB00808,Indapamide
,3311532,plasma half-life,"The plasma half-life of etozolin and ozolinone are 2 and 10 hours, respectively.",Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,2,68493,DB00808,Indapamide
,3311532,plasma half-life,"The plasma half-life of etozolin and ozolinone are 2 and 10 hours, respectively.",Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,10,68494,DB00808,Indapamide
,3311532,plasma half-life,The plasma half-life is approximately 17 hours.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,17,68495,DB00808,Indapamide
,3311532,Apparent volume of distribution,Apparent volume of distribution averaged 686 L and renal clearance is 7.2 L/h.,Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,686,68496,DB00808,Indapamide
,3311532,renal clearance,Apparent volume of distribution averaged 686 L and renal clearance is 7.2 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],7.2,68497,DB00808,Indapamide
,3311532,Gastrointestinal uptake,Gastrointestinal uptake is at least 80%.,Clinical pharmacokinetics of some newer diuretics. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,80,68498,DB00808,Indapamide
,3311532,Protein binding,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),,80,68499,DB00808,Indapamide
,3311532,terminal plasma half-life,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,15,68500,DB00808,Indapamide
,3311532,apparent volume of distribution,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,25,68501,DB00808,Indapamide
,3311532,Renal clearance,Renal clearance is 0.3 L/h and non-renal clearance 0.9 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.3,68502,DB00808,Indapamide
,3311532,non-renal clearance,Renal clearance is 0.3 L/h and non-renal clearance 0.9 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.9,68503,DB00808,Indapamide
,3311532,protein binding,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,65,68504,DB00808,Indapamide
,3311532,apparent volume of distribution,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [kg],1,68505,DB00808,Indapamide
,3311532,terminal half-life,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,10 to 20,68506,DB00808,Indapamide
,3311532,non-renal clearance,"Elimination is mainly non-renal, and non-renal clearance ranges between 0.5 and 1.32 L/h.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.5 and 1.32,68507,DB00808,Indapamide
,3311532,Protein binding,Protein binding in healthy subjects is about 95%.,Clinical pharmacokinetics of some newer diuretics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,95,68508,DB00808,Indapamide
,3311532,plasma half-life,The plasma half-life of the drug is about 1 hour and apparent volume of distribution averages about 17 L.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,1,68509,DB00808,Indapamide
,3311532,apparent volume of distribution,The plasma half-life of the drug is about 1 hour and apparent volume of distribution averages about 17 L.,Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,17,68510,DB00808,Indapamide
,3311532,Renal,"Renal and non-renal clearance are about 6 L/h, although renal clearance is decreased in renal failure: this decrease is correlated with glomerular filtration rate.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],6,68511,DB00808,Indapamide
,3311532,non-renal clearance,"Renal and non-renal clearance are about 6 L/h, although renal clearance is decreased in renal failure: this decrease is correlated with glomerular filtration rate.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],6,68512,DB00808,Indapamide
,6869203,Binding,Binding to plasma proteins is approximately 76%.,Pharmacokinetics and clinical pharmacology of indapamide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869203/),%,76,71526,DB00808,Indapamide
,6869203,terminal half-life,"Disappearance of indapamide from the blood is biphasic, with a terminal half-life of approximately 16 hours.",Pharmacokinetics and clinical pharmacology of indapamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869203/),h,16,71527,DB00808,Indapamide
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,85.9,97193,DB00808,Indapamide
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,93.6,97194,DB00808,Indapamide
,23798332,total run time,The total run time was 2.5 min.,Development and validation of automated SPE-LC-MS/MS method for determination of indapamide in human whole blood and its application to real study samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23798332/),min,2.5,110365,DB00808,Indapamide
,23798332,absolute recoveries,The absolute recoveries of indapamide were 90.51-93.90%.,Development and validation of automated SPE-LC-MS/MS method for determination of indapamide in human whole blood and its application to real study samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23798332/),%,90.51-93.90,110366,DB00808,Indapamide
,27270416,run time,Reversed-phase chromatography using acetonitrile and 0.5% formic acid solution (pH 2.56) was used for separation in a run time of 4.0 min.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),min,4.0,136451,DB00808,Indapamide
,27270416,m/,The analytes were detected in the negative ion mode using selective reaction monitoring (SRM) of the transitions at m/z 271.2 → 107.8 for arbutin and 364.3 → 189.0 for indapamide.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),,271.2,136452,DB00808,Indapamide
,27270416,m/,The analytes were detected in the negative ion mode using selective reaction monitoring (SRM) of the transitions at m/z 271.2 → 107.8 for arbutin and 364.3 → 189.0 for indapamide.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),,107.8,136453,DB00808,Indapamide
,27270416,m/,The analytes were detected in the negative ion mode using selective reaction monitoring (SRM) of the transitions at m/z 271.2 → 107.8 for arbutin and 364.3 → 189.0 for indapamide.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),,364.3,136454,DB00808,Indapamide
,27270416,m/,The analytes were detected in the negative ion mode using selective reaction monitoring (SRM) of the transitions at m/z 271.2 → 107.8 for arbutin and 364.3 → 189.0 for indapamide.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),,189.0,136455,DB00808,Indapamide
,27270416,response,The method has the following performance characteristics: a reliable response range of 7.5-5250.0 ng/mL with correlation coefficients (r) of >0.995.,Determination of Arbutin in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study After Oral Administration of the Extract of Vaccinium vitis-idaea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27270416/),[ng] / [ml],7.5-5250.0,136456,DB00808,Indapamide
,25660911,enhancing ratio (ER),"Then, to simultaneously up-regulate the amounts of the two drugs, an enhancer combination of 15.8% Span80 (SP), 6.0% Azone (AZ) and 2.2% N-methyl pyrrolidone (NMP) was obtained by central composite design and exhibited an outstanding and simultaneous enhancement on IND and BSP with enhancing ratio (ER) of 4.52 and 3.49, respectively.",Dual-directional regulation of drug permeating amount by combining the technique of ion-pair complexation with chemical enhancers for the synchronous permeation of indapamide and bisoprolol in their compound patch through rabbit skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660911/),,4.52,156820,DB00808,Indapamide
,25660911,enhancing ratio (ER),"Then, to simultaneously up-regulate the amounts of the two drugs, an enhancer combination of 15.8% Span80 (SP), 6.0% Azone (AZ) and 2.2% N-methyl pyrrolidone (NMP) was obtained by central composite design and exhibited an outstanding and simultaneous enhancement on IND and BSP with enhancing ratio (ER) of 4.52 and 3.49, respectively.",Dual-directional regulation of drug permeating amount by combining the technique of ion-pair complexation with chemical enhancers for the synchronous permeation of indapamide and bisoprolol in their compound patch through rabbit skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660911/),,3.49,156821,DB00808,Indapamide
,16320942,maximum blood concentrations (C(max)),"The maximum blood concentrations (C(max)) were 60.3 +/- 22.6 microg/L and 57.6 +/- 18.7 microg/L at 13.1 +/- 6.9 h and 18.3 +/- 7.4 h, the times to reach the peak concentration (T(max)), for the test and reference tablets, respectively.",Rapid and sensitive determination of indapamide in human blood by liquid chromatography with electrospray ionization mass spectrometric detection: application to a bioequivalence study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320942/),[μg] / [l],60.3,177677,DB00808,Indapamide
,16320942,maximum blood concentrations (C(max)),"The maximum blood concentrations (C(max)) were 60.3 +/- 22.6 microg/L and 57.6 +/- 18.7 microg/L at 13.1 +/- 6.9 h and 18.3 +/- 7.4 h, the times to reach the peak concentration (T(max)), for the test and reference tablets, respectively.",Rapid and sensitive determination of indapamide in human blood by liquid chromatography with electrospray ionization mass spectrometric detection: application to a bioequivalence study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320942/),[μg] / [l],57.6,177678,DB00808,Indapamide
,16320942,relative bioavailability,"The relative bioavailability of the test tablets was 110.1 +/- 34.5%, compared with the reference tablets.",Rapid and sensitive determination of indapamide in human blood by liquid chromatography with electrospray ionization mass spectrometric detection: application to a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320942/),%,110.1,177679,DB00808,Indapamide
,16781839,plasma extraction recovery,The mean plasma extraction recovery of indapamide was 90.5-93.9%.,A sensitive LC-ESI-MS method for the determination of indapamide in human plasma: method and clinical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16781839/),%,90.5-93.9,179363,DB00808,Indapamide
,9918600,IC50,"Finally, experiments performed with the patch-clamp technique demonstrated unequivocal block of the rapid component of the delayed rectifier (IKr) by DPH; however, IC50 determined for block of IKr (3 x 10(-5) M) is approximately 40-fold greater than plasma concentrations of the drug measured at usual dosages (7 x 10(-7) M).",Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918600/),M,3 x 10(-5),204696,DB00808,Indapamide
,9918600,IC50,"Finally, experiments performed with the patch-clamp technique demonstrated unequivocal block of the rapid component of the delayed rectifier (IKr) by DPH; however, IC50 determined for block of IKr (3 x 10(-5) M) is approximately 40-fold greater than plasma concentrations of the drug measured at usual dosages (7 x 10(-7) M).",Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918600/),,7,204697,DB00808,Indapamide
,33314205,flow rate,"Ammonium acetate and methanol, pumped at a flow rate of 0.3 ml/min, were used as a mobile phase.","Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS/MS method: Application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314205/),[ml] / [min],0.3,212489,DB00808,Indapamide
,7106164,area under the blood concentration versus time curve,"The area under the blood concentration versus time curve, extrapolated to infinity was essentially the same for all three formulations (4.2, 4.7, and 4.4 microgram-h/ml).",Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),[μgram-h] / [ml],4.2,233354,DB00808,Indapamide
,7106164,area under the blood concentration versus time curve,"The area under the blood concentration versus time curve, extrapolated to infinity was essentially the same for all three formulations (4.2, 4.7, and 4.4 microgram-h/ml).",Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),[μgram-h] / [ml],4.7,233355,DB00808,Indapamide
,7106164,area under the blood concentration versus time curve,"The area under the blood concentration versus time curve, extrapolated to infinity was essentially the same for all three formulations (4.2, 4.7, and 4.4 microgram-h/ml).",Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),[μgram-h] / [ml],4.4,233356,DB00808,Indapamide
,7106164,time of maximum blood concentration,Statistical comparison of the blood levels from the two tablets showed that one tablet had a significantly shorter time of maximum blood concentration (2.3 vs 3.5).,Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),,2.3,233357,DB00808,Indapamide
,7106164,time of maximum blood concentration,Statistical comparison of the blood levels from the two tablets showed that one tablet had a significantly shorter time of maximum blood concentration (2.3 vs 3.5).,Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),,3.5,233358,DB00808,Indapamide
,7106164,Cmax,Cmax(333ng/ml) and tmax (0.7h) values for the solution were significantly higher than either tablet.,Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),[ng] / [ml],333,233359,DB00808,Indapamide
,7106164,tmax,Cmax(333ng/ml) and tmax (0.7h) values for the solution were significantly higher than either tablet.,Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),h,0.7,233360,DB00808,Indapamide
,7106164,half-life (beta-phase),"The average half-life (beta-phase) for all three formulations was 15 h, while the average systemic clearance was 20 ml/min.",Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),h,15,233361,DB00808,Indapamide
,7106164,systemic clearance,"The average half-life (beta-phase) for all three formulations was 15 h, while the average systemic clearance was 20 ml/min.",Pharmacokinetics and bioavailability of indapamide--a new antihypertensive drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106164/),[ml] / [min],20,233362,DB00808,Indapamide
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB00808,Indapamide
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB00808,Indapamide
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB00808,Indapamide
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB00808,Indapamide
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB00808,Indapamide
,23447043,Cmax,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[ng] / [ml],49.53,247578,DB00808,Indapamide
,23447043,t1/2,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[ng] / [ml],47.79,247579,DB00808,Indapamide
,23447043,AUC0-τ,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[ng] / [ml],47.79,247580,DB00808,Indapamide
,23447043,AUC0-τ,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[h·ng] / [ml],859.51,247581,DB00808,Indapamide
,23447043,AUC0-τ,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[h·ng] / [ml],934.35,247582,DB00808,Indapamide
,23447043,AUC0-∞,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[h·ng] / [ml],934.35,247583,DB00808,Indapamide
,23447043,AUC0-∞,"The values of Cmax, Tmax, t1/2, AUC0-τ, AUC0-∞ for test and reference formulations were 49.53±5.53 and 47.79±4.68 ng/mL, 1.9±0.6 and 2.0±0.5 h, 22.49±5.93 and 23.23±4.48 h, 859.51±160.92 and 840.90±170.62 ng · h/mL, 934.35±190.60 and 919.52±179.74 ng · h/mL, respectively.",Pharmacokinetics and bioequivalence study of two indapamide formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447043/),[h·ng] / [ml],919.52,247584,DB00808,Indapamide
,10796061,dose-normalised Cmax,Following a single oral administration the SR formulation had a lower dose-normalised Cmax compared to the IR formulation (17.6 +/- 6.3 vs.,Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),,17.6,247770,DB00808,Indapamide
,10796061,t(max),"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,12.3,247771,DB00808,Indapamide
,10796061,t(max),"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,0.8,247772,DB00808,Indapamide
,10796061,t75,"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,15.3,247773,DB00808,Indapamide
,10796061,t75,"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,1.8,247774,DB00808,Indapamide
,10796061,dose-normalised AUC,"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),[h·ng] / [ml],559,247775,DB00808,Indapamide
,10796061,dose-normalised AUC,"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),[h·ng] / [ml],564,247776,DB00808,Indapamide
,10796061,t(1/2z),"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,14.8,247777,DB00808,Indapamide
,10796061,t(1/2z),"39.3 +/- 11.0 ng x mL(-1), respectively), a much longer t(max) (12.3 +/- 0.4 vs. 0.8 +/- 0.3 h) and a greater t75 (15.3 +/- 6.1 vs. 1.8 +/- 1.4 h) but there were no differences in dose-normalised AUC (559 +/- 125 and 564 +/- 146 ng x h x mL(-1)) nor in t(1/2z) values (14.8 +/- 2.8 vs. 18.4 +/- 13.4 h).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),h,18.4,247778,DB00808,Indapamide
,10796061,AUC,"After dose correction there wasno change in AUC, (726 +/- 207 and 690 +/- 183 ng x mL(-1) x h for SR and IR, respectively).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),[h·ng] / [ml],726,247779,DB00808,Indapamide
,10796061,AUC,"After dose correction there wasno change in AUC, (726 +/- 207 and 690 +/- 183 ng x mL(-1) x h for SR and IR, respectively).",Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10796061/),[h·ng] / [ml],690,247780,DB00808,Indapamide
,16111851,LOQ (s/n,The LOQ (s/n = 10) of the method was 10 ng/ml.,A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[ng] / [ml],10,254340,DB00808,Indapamide
,16111851,C(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[ng] / [ml],331.0,254341,DB00808,Indapamide
,16111851,AUC(0-48),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254342,DB00808,Indapamide
,16111851,AUC(0-48),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254343,DB00808,Indapamide
,16111851,AUC(0-infinity),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254344,DB00808,Indapamide
,16111851,AUC(0-infinity),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254345,DB00808,Indapamide
,16111851,T(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254346,DB00808,Indapamide
,16111851,T(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254347,DB00808,Indapamide
,16111851,t(1/2),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),h,3.2,254348,DB00808,Indapamide
,16111851,t(1/2),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),h,17.3,254349,DB00808,Indapamide
,23831701,resolution factor (Rs),"Using the chromatographic conditions described, indapamide enantiomers were well resolved with a resolution factor (Rs) of at least 2.0 and with retention times of 19.2 and 23.3min, respectively.",Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of indapamide enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831701/),,2.0,264933,DB00808,Indapamide
,23831701,retention times,"Using the chromatographic conditions described, indapamide enantiomers were well resolved with a resolution factor (Rs) of at least 2.0 and with retention times of 19.2 and 23.3min, respectively.",Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of indapamide enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831701/),min,19.2,264934,DB00808,Indapamide
,23831701,retention times,"Using the chromatographic conditions described, indapamide enantiomers were well resolved with a resolution factor (Rs) of at least 2.0 and with retention times of 19.2 and 23.3min, respectively.",Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of indapamide enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831701/),min,23.3,264935,DB00808,Indapamide
greater,23831701,extraction efficiency,The mean extraction efficiency was greater than 86% for each enantiomer.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of indapamide enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23831701/),%,86,264936,DB00808,Indapamide
,19135329,flow rate,"After extraction with ethyl acetate, the chromatographic separation was carried out on a Diamonsil C(18) column (150mmx4.6mm i.d., 5microm particle size, Zhonghuida) protected by a ODS guard column (10mmx4.6mm i.d., 5microm particle size), using acetonitrile-methanol-phosphate buffer (pH 3.0, 30mM) (31:3:66, v/v/v) as mobile phase at a flow rate of 1.0mL/min, and wavelength of the UV detector was set at 281nm.",Development of a high performance liquid chromatography method for quantification of PAC-1 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135329/),,1.,268096,DB00808,Indapamide
